New therapeutic options for gout here and on the horizon
By ARYEH M. ABELES, MD MICHAEL H. PILLINGER, MD | March 8, 2010
Dr Abeles is assistant clinical professor in the department of medicine, division of rheumatology, at the University of Connecticut Health Center in Farmington. Dr Pillinger is associate professor of medicine and pharmacology in the department of medicine, division of rheumatology, at the New York University School of Medicine/NYU Hospital for Joint Diseases in New York and attending physician at the New York Harbor VA Health Care System, New York Campus.
ABSTRACT: No new drug was FDA-approved for gout for close to 45 years, but new drugs are on the market now and others are in development. Established treatments often are effective, but each has limitations. In 2009, the FDA approved a nongeneric colchicine for acute gout. Investigators are exploring anti–interleukin-1β therapy. Anakinra has been studied off-label for acute gout. Rilonacept is being investigated for treatment and prophylaxis of gouty inflammation and canakinumab for acute gout attacks. Clinical trials of a novel urate transporter 1 inhibitor, RDEA594, are under way. Reducing the production of uric acid may be achieved with allopurinol. Febuxostat gained FDA approval in 2009 for managing hyperuricemia in patients with established gout. Rasburicase and pegloticase have been developed for uricase replacement. (J Musculoskel Med. 2010;27:93-100)
http://www.musculoskeletalnetwork.com/gout/content/article/1145622/1533314
Gout - Wikipedia, the free encyclopedia
en.wikipedia.org/wiki/Gout
It has very informative information.Gout is very painful problem of joints.so we have a good treatment of gout for those who want to get rid of from gout.Thanks!
ReplyDeletegout remedies